In this study, we have analysed the effects of histone deacetylase (HDAC) inhibition on estrogen receptor (ER) expression and on its transcriptional activity in response to antiestrogens. In several breast cancer cell lines, trichostatin A (TSA), a potent HDAC inhibitor, strongly decreases ERalpha expression in a dose-dependent manner. This repression is observed independently of the presence of ligand and also occurs in ovarian and endometrial cell lines. In addition, we show that in MCF7 cells bearing a stably transfected reporter plasmid (MELN cells), partial antiestrogens such as 4-OH-tamoxifen (OHTam), raloxifen or LY117018, switch to an agonist activity upon HDAC inhibition. This effect is blocked by the pure antiestrogen ICI182780 and exhibits a half-maximal concentration of OHTam equivalent to its affinity for ERalpha. The TSA-dependent decrease of ERalpha expression is required to induce the agonist switch of OHTam properties as it is lost in cells constitutively expressing exogenous receptors (MELN-ERalpha or ERbeta). By contrast, the transrepression activity of OHTam is abolished by TSA independently of the decrease of ERalpha expression. Interestingly, in MELN-ERalpha, ICI182780 remains inhibitory suggesting the involvement of HDAC-independent mechanisms. Finally, in the absence of TSA, transcriptional activity in response to OHTam is significantly raised in MELN cells expressing low levels of ERalpha after transfection of antisense oligonucleotides. In conclusion, inhibition of HDAC enzymatic activity and modulation of ERalpha levels tightly control the relative agonist activity of partial antiestrogens on a stably integrated reporter transgene.

This article has been cited by other articles:

				M. De los Santos, O. Martinez-Iglesias, and A. Aranda Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells Endocr. Relat. Cancer, December 1, 2007; 14(4): 1021 - 1028. [Abstract] [Full Text] [PDF]

				W. Fiskus, Y. Ren, A. Mohapatra, P. Bali, A. Mandawat, R. Rao, B. Herger, Y. Yang, P. Atadja, J. Wu, et al. Hydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-{alpha} Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 90 Clin. Cancer Res., August 15, 2007; 13(16): 4882 - 4890. [Abstract] [Full Text] [PDF]

				S. Wagner, S. Weber, M. A. Kleinschmidt, K. Nagata, and U.-M. Bauer SET-mediated Promoter Hypoacetylation Is a Prerequisite for Coactivation of the Estrogen-responsive pS2 Gene by PRMT1 J. Biol. Chem., September 15, 2006; 281(37): 27242 - 27250. [Abstract] [Full Text] [PDF]

				M. Y. Kim, E. M. Woo, Y. T. E. Chong, D. R. Homenko, and W. L. Kraus Acetylation of Estrogen Receptor {alpha} by p300 at Lysines 266 and 268 Enhances the Deoxyribonucleic Acid Binding and Transactivation Activities of the Receptor Mol. Endocrinol., July 1, 2006; 20(7): 1479 - 1493. [Abstract] [Full Text] [PDF]

				M-B Debril, L Dubuquoy, J-N Feige, W Wahli, B Desvergne, J Auwerx, and L Gelman Scaffold attachment factor B1 directly interacts with nuclear receptors in living cells and represses transcriptional activity J. Mol. Endocrinol., December 1, 2005; 35(3): 503 - 517. [Abstract] [Full Text] [PDF]

				H. Leong, J. R. Sloan, P. D. Nash, and G. L. Greene Recruitment of Histone Deacetylase 4 to the N-Terminal Region of Estrogen Receptor {alpha} Mol. Endocrinol., December 1, 2005; 19(12): 2930 - 2942. [Abstract] [Full Text] [PDF]

				W. Rocha, R. Sanchez, J. Deschenes, A. Auger, E. Hebert, J. H. White, and S. Mader Opposite Effects of Histone Deacetylase Inhibitors on Glucocorticoid and Estrogen Signaling in Human Endometrial Ishikawa Cells Mol. Pharmacol., December 1, 2005; 68(6): 1852 - 1862. [Abstract] [Full Text] [PDF]